Boardroom Alpha
Meeting calendar
LASE · Special meeting · Friday, June 26, 2026

Laser Photonics Corp

8 nominees · 2 ballot items.

Approval of two warrant inducement agreements: the March Warrant Inducement Agreement (Series A-3 and A-4 replacement warrants, reduced exercise price) and the April Warrant Inducement Agreement (Series A-5 and A-6 new warrants, reduced exercise price).

Market cap
$36M
1Y TSR
-79.9%
Board grade
D
Record date
May 13, 2026
Filing
DEF 14A
Meeting concluded · Jun 26, 2026

Follow how the vote landed and what changed on Laser Photonics Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot2

  1. 1

    Approval of the March Warrant Inducement Agreement

    ManagementBoard: FOR

    Approve the warrant inducement agreement dated March 15, 2026, which provides replacement Series A-3 and A-4 warrants with reduced exercise price of $1.08 per share and requires registration of the shares underlying those warrants.

    More detail

    This management proposal requests shareholder approval of the March Warrant Inducement Agreement entered into on March 15, 2026 with holders of existing Series A and Series B warrants. The agreement provides the warrant holders an inducement to exercise by offering replacement Series A-3 and A-4 warrants exercisable at a reduced exercise price of $1.08 per share (down from $3.40), thereby accelerating potential cash proceeds to the Company; the company received gross proceeds of $1,483,520.40 in connection with the inducement. The replacement warrants require registration of the 2,747,260 underlying shares via an S-1 that must be filed within 30 days and declared effective within prescribed timelines, with filing/timing covenants and associated restrictions on issuance of other securities and variable rate transactions for limited periods. Management frames the transaction as necessary to fund the Company's business plan, increase near-term liquidity and potentially enable further financing if the new warrants are exercised; the Board recommends a FOR vote, stating that proceeds have funded operations and could result in additional financing. Key governance considerations include dilution to existing shareholders from issuance and exercise of nearly 2.75M shares, the material reduction in exercise price (from $3.40 to $1.08) which transfers value to warrant holders, and transferability/term differences between Series A-3 and A-4 (longer five-year term for A-3 vs eighteen months for A-4) which affect the timing of potential dilution. The requirement to register shares and the company's related filing covenants create execution risk (including potential cash penalties per the April agreement precedent) and timeline constraints; investors should weigh whether the immediate liquidity benefit and operational funding justify the dilution and contractual restrictions. The Board’s recommendation is grounded in the immediate proceeds and anticipated ability to file the registration statement; however, shareholders should consider potential long-term share count impacts, the control implications if major existing holders participate, and whether the reduced strike price aligns with shareholder interests given the company’s recent financing and related party transactions.

  2. 2

    Approval of the April Warrant Inducement Agreement

    ManagementBoard: FOR

    Approve the warrant inducement agreement dated April 26, 2026, which offers Series A-5 and A-6 unregistered warrants with an exercise price of $0.975 per share and requires registration of the underlying shares.

    More detail

    This management proposal requests shareholder approval of the April Warrant Inducement Agreement entered into on April 26, 2026 with holders of existing Series A-1 and Series A-2 warrants. The agreement provides the warrant holders new Series A-5 and A-6 warrants exercisable at $0.975 per share (down from the original $0.70 exercise price of the existing warrants) in exchange for cash, yielding gross proceeds of $4,000,559.50 to the Company. The transaction requires the Company to file a resale S-1 to register 11,430,170 shares underlying the new warrants within 30 days and be subject to effectiveness timing constraints and related filing covenants; failure to meet these timelines may trigger cash penalties under the agreement. The agreement includes beneficial ownership limitations on exercises (4.99% or 9.99% at holders’ election), placement agent fees and warrants to H.C. Wainwright, and restrictions on issuing other securities or entering variable rate transactions for set periods. Management argues the financing provides significant near-term liquidity to fund operations and could lead to further financing upon exercise; the Board recommends a FOR vote. Material considerations for shareholders include substantial dilution risk (over 11 million underlying shares), the grant of placement agent warrants and fees, potential cash penalties for filing delays, and the reduced exercise price that accelerates potential dilution; these items should be considered against the immediate capital infusion and strategic need for funding.

Director elections

Nominees on the ballot8

Troy Parkos
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
0.8 yrs
Ownership

Top institutional holders10

Latest 13F quarter
1VANGUARD CAPITAL MANAGEMENT LLC2.9%1,439,265$2M
2SUSQUEHANNA INTERNATIONAL GROUP, LLP0.8%381,136$629K
3RENAISSANCE TECHNOLOGIES LLC0.7%344,055$568K
4GEODE CAPITAL MANAGEMENT, LLC0.5%252,915$417K
5BlackRock, Inc.0.4%202,392$334K
6VANGUARD FIDUCIARY TRUST CO0.4%179,165$296K
7MARSHALL WACE, LLP0.3%166,721$275K
8Virtu Financial LLC0.3%127,170$210K
9UBS Group AG0.3%126,043$208K
10Scientech Research LLC0.2%122,789$203K
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Laser Photonics Corp 2026 special meeting?
Laser Photonics Corp (LASE) holds its 2026 special shareholder meeting on Friday, June 26, 2026.
What is the record date for the Laser Photonics Corp 2026 meeting?
The record date for the Laser Photonics Corp 2026 meeting is Wednesday, May 13, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Laser Photonics Corp's 2026 meeting?
The board is presenting 8 director nominees at the Laser Photonics Corp 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Laser Photonics Corp 2026 meeting?
Shareholders will vote on 2 proposals at the Laser Photonics Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer